DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03066453 (ClinicalTrials.gov)	June 13, 2017	23/2/2017	Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis	Evaluation of an Antibiotic Treatment With 14 Days of Intravenous Tobramycin Versus the Same Antibiotic Associated With 5 Days of Intravenous Tobramycin Followed by Tobramycin Aerosol for 9 Days in Cystic Fibrosis.	Cystic Fibrosis	Drug: Tobi Inhalant Product;Drug: Nebcin	University Hospital, Lille	NULL	Recruiting	8 Years	N/A	All	97	Phase 3	France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03066453
(ClinicalTrials.gov)

June 13, 2017

23/2/2017

Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis

Evaluation of an Antibiotic Treatment With 14 Days of Intravenous Tobramycin Versus the Same Antibiotic Associated With 5 Days of Intravenous Tobramycin Followed by Tobramycin Aerosol for 9 Days in Cystic Fibrosis.

Cystic Fibrosis

Drug: Tobi Inhalant Product;Drug: Nebcin

University Hospital, Lille

NULL

Recruiting

8 Years

N/A

All

Phase 3

France